益肾蠲痹丸联合甲氨蝶呤片治疗类风湿关节炎的临床效果

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (622 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Yishen Juanbi Pills combined with Methotrexate Tablets in the treatment of rheumatoid arthritis (RA). Methods A total of 96 RA patients admitted to Baoding Second Central Hospital from April 2020 to May 2021 were selected and they were divided into control group and observation group according to random number table method, with 48 patients in each group. The control group was treated with Methotrexate Tablets, and the observation group was treated with Yishen Juanbi Pills on the basis of the control group for six months. Clinical efficacy, clinical symptoms, and adverse reactions were compared between the two groups, and serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF) titer, matrix metalloproteinase-1 (MMP-1), MMP-3, and anti streptolysin “O” (ASO) were detected and compared before and after six months of treatment. Results After six months of treatment, rest pain time, morning stiffness time, joint swelling number and joint tenderness index in both groups were lower than those before treatment, and those in the observation group was lower than those in the control group, the differences were statistically significant (P ＜ 0.05). After six months of treatment, the hand grip strength of both groups was increased compared with that before treatment, and that of observation group was higher than that of control group, the differences were statistically significant (P ＜ 0.05). After six months of treatment, CRP, ESR, RF, MMP-1, MMP-3, and ASO in both groups were lower than before treatment, and those in the observation group were lower than those in the control group, the differences were statistically significant (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). After six months of treatment, the clinical effect of observation group was better than that of control group, the difference was statistically significant (P ＜ 0.05). Conclusion Yishen Juanbi Pills combined with Methotrexate Tablets has significant efficacy in the treatment of RA patients, which can effectively improve the clinical symptoms of patients and reduce the level of inflammatory factors, with good safety.

Key words： Yishen Juanbi Pills Methotrexate Tablets Rheumatoid arthritis Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XUE Hongwei ZHAO Heyi MA Guoju

Cite this article:

XUE Hongwei ZHAO Heyi MA Guoju. Clinical effect of Yishen Juanbi Pills combined with Methotrexate Tablets in the treatment of rheumatoid arthritis#br#[J]. 中国医药导报, 2022, 19(12): 92-95.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I12/92

[1] 王静，赵庆杰，卓小斌，等.类风湿性关节炎的治疗药物研究进展[J].药学实践杂志，2019，37（6）：485-490.
[2] 田新平，李梦涛，曾小峰.我国类风湿关节炎诊治现状与挑战：来自中国类风湿关节炎2019年年度报告[J].中华内科杂志，2021，60（7）：593-598.
[3] 王长磊，孔纯玉，戚务芳.类风湿关节炎和骨关节炎伴发代谢综合征的患病率和临床特征[J].中华风湿病学杂志，2020，24（1）：24-32.
[4] 吴晨，魏昀，高慧琴.基于网络药理学的类风湿关节炎药物治疗研究进展[J].中医药学报，2020，48（2）：67-71.
[5] 徐进，吴小芬.悬灸联合甲氨蝶呤治疗早期类风湿关节炎疗效及对外周血炎症指标、氧化应激的影响[J].上海针灸杂志，2020，39（6）：743-747.
[6] 李萍，彭全成.益肾蠲痹丸治疗类风湿关节炎的Meta分析[J].中成药，2018，40（12）：2650-2655.
[7] 中华医学会风湿病学分会.类风湿关节炎诊断及治疗指南[J].中华风湿病学杂志，2010，14（4）：265-270.
[8] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：116-119.
[9] 李雪，苏茵.早期类风湿关节炎的诊断与治疗[J].中华内科杂志，2020，59（9）：724-727.
[10] 杨传刚，王冬.免疫细胞参与类风湿关节炎发病的研究进展[J].国际老年医学杂志，2020，41（1）：62-64.
[11] 王言，吴虹，邓然，等.关节滑膜炎性微环境对类风湿关节炎发生发展作用的研究进展[J].中国药理学通报，2020， 36（6）：754-759.
[12] 林悦静，柯生辉，陈彩鸾.甲氨蝶呤联合当归四逆汤对类风湿关节炎患者关节疼痛及实验室指标的影响[J].中国现代医药杂志，2020，22（5）：52-54.
[13] 亚太医学生物免疫学会儿童过敏免疫风湿病分会，《中国实用儿科杂志》编辑委员会.儿童免疫相关性疾病临床实用热点问题专家建议系列之一——甲氨蝶呤在中国儿童风湿性疾病中的应用建议[J].中国实用儿科杂志，2020，35（3）：169-173.
[14] 张文辉，王维，钟意，等.甲氨蝶呤、硫酸羟氯喹联合小剂量甲泼尼龙对老年类风湿关节炎患者外周血淋巴细胞亚群的影响[J].中国老年学杂志，2020，40（11）：2366-2369.
[15] 陆继娣，葛显应，王海林，等.桂枝芍药知母汤联合甲氨蝶呤治疗类风湿关节炎寒湿痹阻证的效果[J].中国医药导报，2021，18（18）：160-163.
[16] 郑庄铭，陈进春，邱明山.探讨类风湿关节炎与中医证素学的研究现状与问题[J].风湿病与关节炎，2020，9（1）：54-56.
[17] 信建军.益肾蠲痹丸辅治类风湿关节炎活动期临床观察[J].实用中医药杂志，2021，37（7）：1152-1153.
[18] 赵玲玉.国医大师朱良春“治未病”思想在痹病临床中的应用探析[J].浙江中医药大学学报，2021，45（1）：23-27.
[19] 宋健，于丽，王文华，等.类风湿性关节炎患者ACCP抗体联合风湿四项RF、ESR、CRP、ASO检测的临床价值[J].中国地方病防治杂志，2016，31（1）：77-78.
[20] 庄建阳，刘雪梅，代思明，等.PPAR-γ、MMP-3及Bcl6水平变化与RA病情活动性和病理评分的相关性[J].分子诊断与治疗杂志，2021，13（8）：1301-1304.
[21] 李小飞，高健，缪娴静，等.RA患者血清RF、MMP-3及抗CarP抗体联合检测的诊断价值[J].西部医学，2021， 33（7）：1048-1051.
[22] 李佳芯.血清APN、MMP-1、MMP-3水平检测在类风湿性关节炎患者病情评估中的价值[J].中国民康医学，2021，33（16）：92-94.
[23] 李婷，郑宝林，叶美杏，等.通痹胶囊治疗类风湿关节炎的疗效及对微循环和血清MMP-1、MMP-3的影响[J].现代生物医学进展，2020，20（16）：3117-3120.
[24] 王晶晶，刘静，裴天仙，等.益肾蠲痹丸对Ⅱ型胶原致关节炎大鼠踝关节组织病理改变的影响及其机制研究[J].中草药，2016，47（17）：3064-3069.
[25] 孙云柯，姚金龙，吴睿哲，等.风湿性关节炎治疗用药探讨[J].中国医药科学，2021，11（3）：83-85.
[26] 谢志敏，吴德鸿，刘东洋，等.中西医结合治疗类风湿关节炎疗效与安全性的系统评价[J].中华中医药学刊，2019， 37（2）：290-296.